Modality
Degrader
MOA
GLP-1/GIP
Target
KRASG12C
Pathway
Sphingolipid
SMA
Development Pipeline
Preclinical
Nov 2025
→ Jun 2025
PreclinicalCurrent
NCT05637958
735 pts·SMA
2025-11→2025-06·Active
735 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-279mo agoInterim· SMA
Trial Timeline
Q3Q4
Preclinical
Active
Catalysts
Interim
2025-06-27 · 9mo ago
SMA
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05637958 | Preclinical | SMA | Active | 735 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |